| Document Date: 2013-09-18 16:39:55
Open Document File Size: 344,15 KBShare Result on Facebook
City London / Paris / / Company Value Assessment Working Group / While / Multiple Working Group / / Continent Europe / / Country France / Netherlands / Italy / United Kingdom / / IndustryTerm healthcare innovation / pharmaceuticals / stakeholder / healthcare system / post-launch evidence collection tools / post-launch evidence generation tools / healthcare budget holders / umbrella protocols / decision makers / health technology assessors / basic registry infrastructure / healthcare resources / improved collection tools / payment systems / postlaunch evidence generation tools / health systems / pharmaceutical / healthcare / lower quality healthcare / healthcare systems / healthcare leaders / personalised healthcare / focused on advancing European healthcare innovation / / MedicalCondition cancer / disease / specific cancer / / MedicalTreatment immunosuppression / / Organization civil society / European Union / / Person Another / / Position researcher / HTA leader / industry representative / / Product Herceptin / Avastin / / Technology umbrella protocols / specific technology / /
SocialTag |
The Post-launch Value Assessment Working Group (PVA WG) convened for its launch meeting on 20 September 2012 in London. Participants gathered to resolve issues concerning uncertainty about the value of medicines at the t